$UTMD
UTAH MEDICAL PRODUCTS INC

2024 Q4 Form 10-Q Financial Statement

#000181188424000022 Filed on November 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $10.01M
YoY Change -19.99%
Cost Of Revenue $4.203M
YoY Change -18.32%
Gross Profit $5.802M
YoY Change -21.16%
Gross Profit Margin 57.99%
Selling, General & Admin $2.287M
YoY Change -29.67%
% of Gross Profit 39.42%
Research & Development $172.0K
YoY Change 24.64%
% of Gross Profit 2.96%
Depreciation & Amortization $728.0K
YoY Change -58.87%
% of Gross Profit 12.55%
Operating Expenses $2.459M
YoY Change -27.46%
Operating Profit $3.343M
YoY Change -15.77%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $836.0K
YoY Change 2.96%
Pretax Income $4.179M
YoY Change -12.59%
Income Tax $616.0K
% Of Pretax Income 14.74%
Net Earnings $3.563M
YoY Change -9.45%
Net Earnings / Revenue 35.61%
Basic Earnings Per Share $1.02
Diluted Earnings Per Share $1.02
COMMON SHARES
Basic Shares Outstanding 3.392M shares 3.477M shares
Diluted Shares Outstanding 3.478M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $88.45M
YoY Change 0.29%
Cash & Equivalents $88.45M
Short-Term Investments
Other Short-Term Assets $377.0K
YoY Change -14.71%
Inventory $9.107M
Prepaid Expenses
Receivables $3.720M
Other Receivables $0.00
Total Short-Term Assets $101.7M
YoY Change -0.19%
LONG-TERM ASSETS
Property, Plant & Equipment $10.42M
YoY Change 0.71%
Goodwill $14.03M
YoY Change 4.49%
Intangibles $3.592M
YoY Change -36.15%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $28.04M
YoY Change -4.62%
TOTAL ASSETS
Total Short-Term Assets $101.7M
Total Long-Term Assets $28.04M
Total Assets $129.7M
YoY Change -1.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $999.0K
YoY Change 95.5%
Accrued Expenses $2.436M
YoY Change -33.55%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.435M
YoY Change -17.76%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $698.0K
YoY Change -44.43%
Total Long-Term Liabilities $698.0K
YoY Change -44.43%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.435M
Total Long-Term Liabilities $698.0K
Total Liabilities $5.497M
YoY Change -27.11%
SHAREHOLDERS EQUITY
Retained Earnings $134.1M
YoY Change -0.81%
Common Stock $34.00K
YoY Change -93.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $124.2M
YoY Change
Total Liabilities & Shareholders Equity $129.7M
YoY Change -1.18%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income $3.563M
YoY Change -9.45%
Depreciation, Depletion And Amortization $728.0K
YoY Change -58.87%
Cash From Operating Activities $3.856M
YoY Change -24.69%
INVESTING ACTIVITIES
Capital Expenditures $89.00K
YoY Change -53.16%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$89.00K
YoY Change -53.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -4.918M
YoY Change 377.48%
NET CHANGE
Cash From Operating Activities 3.856M
Cash From Investing Activities -89.00K
Cash From Financing Activities -4.918M
Net Change In Cash -1.151M
YoY Change -129.51%
FREE CASH FLOW
Cash From Operating Activities $3.856M
Capital Expenditures $89.00K
Free Cash Flow $3.767M
YoY Change -23.59%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Central Index Key
EntityCentralIndexKey
0000706698
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2024Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4203000 usd
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2287000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
172000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
2459000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
3343000 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
836000 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
4179000 usd
CY2024Q3 us-gaap Profit Loss
ProfitLoss
3563000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.02
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.02
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3478000 shares
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1432000 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
4995000 usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-12575
dei Entity Registrant Name
EntityRegistrantName
UTAH MEDICAL PRODUCTS INC
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
UT
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0342734
dei Entity Address Address Line1
EntityAddressAddressLine1
7043 South 300 West
dei Entity Address City Or Town
EntityAddressCityOrTown
Midvale
dei Entity Address State Or Province
EntityAddressStateOrProvince
UT
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
84047
dei City Area Code
CityAreaCode
801
dei Local Phone Number
LocalPhoneNumber
566-1200
dei Security12b Title
Security12bTitle
Common stock, $0.01 par value
dei Trading Symbol
TradingSymbol
UTMD
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3391620 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
88452000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
92868000 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3720000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3391000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
9107000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
9582000 usd
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
377000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
428000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
101656000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
106269000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10419000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10551000 usd
CY2024Q3 us-gaap Goodwill
Goodwill
14027000 usd
CY2023Q4 us-gaap Goodwill
Goodwill
13692000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
55899000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
54296000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
52307000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
49350000 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3592000 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
4946000 usd
CY2024Q3 us-gaap Assets
Assets
129694000 usd
CY2023Q4 us-gaap Assets
Assets
135458000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
999000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
769000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2436000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3941000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3435000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4710000 usd
CY2024Q3 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
779000 usd
CY2023Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
1120000 usd
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
698000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
698000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
299000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
295000 usd
CY2024Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
286000 usd
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
322000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
5497000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
7145000 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3441000 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3441000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3630000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3630000 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
34000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
36000 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Before Tax1
AccumulatedOtherComprehensiveIncomeLossBeforeTax1
-9890000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Before Tax1
AccumulatedOtherComprehensiveIncomeLossBeforeTax1
-10658000 usd
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
0 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
594000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
134053000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
138341000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
124197000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
128313000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
129694000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
135458000 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10005000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12505000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31745000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
37891000 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5146000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
12925000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14951000 usd
CY2024Q3 us-gaap Gross Profit
GrossProfit
5802000 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
7359000 usd
us-gaap Gross Profit
GrossProfit
18820000 usd
us-gaap Gross Profit
GrossProfit
22940000 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3252000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7464000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9693000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
138000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
692000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
414000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
3390000 usd
us-gaap Operating Expenses
OperatingExpenses
8156000 usd
us-gaap Operating Expenses
OperatingExpenses
10107000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
3969000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
10664000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
12833000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
812000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2524000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2239000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
4781000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
13188000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
15072000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
616000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
846000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2216000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2723000 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
3935000 usd
us-gaap Profit Loss
ProfitLoss
10972000 usd
us-gaap Profit Loss
ProfitLoss
12349000 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.1
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.4
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.1
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.39
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3478000 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3629000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3542000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3629000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3639000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3542000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3638000 shares
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1012000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
769000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
41000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2923000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
11741000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
12390000 usd
us-gaap Profit Loss
ProfitLoss
10972000 usd
us-gaap Profit Loss
ProfitLoss
12349000 usd
us-gaap Depreciation
Depreciation
530000 usd
us-gaap Depreciation
Depreciation
465000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1548000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4824000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-6000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-31000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
38000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
39000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-417000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-284000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
184000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
153000 usd
us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
20000 usd
us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
12000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
306000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2133000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-508000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
925000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-54000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-19000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
229000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-712000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1460000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1093000 usd
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
922000 usd
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
4600000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
11894000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
16949000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
221000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
549000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
5000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
27000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-199000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-549000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
390000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
117000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
13259000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 usd
us-gaap Payments Of Dividends
PaymentsOfDividends
3222000 usd
us-gaap Payments Of Dividends
PaymentsOfDividends
3211000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-16091000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3094000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-20000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-149000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4416000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
13157000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
92868000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75052000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
88452000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
88209000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
3713000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
3489000 usd
us-gaap Interest Paid
InterestPaid
0 usd
us-gaap Interest Paid
InterestPaid
0 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
124052000 usd
CY2024Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
53000 usd
CY2024Q3 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
-3866000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1432000 usd
CY2024Q3 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
1038000 usd
CY2024Q3 us-gaap Profit Loss
ProfitLoss
3563000 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
124197000 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
128313000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
390000 usd
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
184000 usd
us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
-13259000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
769000 usd
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
3171000 usd
us-gaap Profit Loss
ProfitLoss
10972000 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
124197000 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
121762000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
36000 usd
CY2023Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
53000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1012000 usd
CY2023Q3 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
1071000 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
3935000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
123702000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
114254000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
117000 usd
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
153000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
41000 usd
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
3212000 usd
us-gaap Profit Loss
ProfitLoss
12349000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
123702000 usd
CY2024Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1356000 usd
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1685000 usd
CY2024Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
1441000 usd
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1503000 usd
CY2024Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
6310000 usd
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
6394000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
9107000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
9582000 usd
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
53000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
53000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
184000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
153000 usd
CY2023Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
0 usd
CY2024Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
0 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10005000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31745000 usd
CY2024Q3 us-gaap Profit Loss
ProfitLoss
3563000 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
3935000 usd
us-gaap Profit Loss
ProfitLoss
10972000 usd
us-gaap Profit Loss
ProfitLoss
12349000 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3478000 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3629000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3542000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3629000 shares
CY2024Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2023Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
10000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
9000 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3478000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3639000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3542000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3638000 shares
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.02
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.1
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.4
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.02
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.1
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.39
CY2024Q4 us-gaap Stock Repurchased And Retired During Period Shares
StockRepurchasedAndRetiredDuringPeriodShares
48905 shares
CY2024Q4 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
3164000 usd
CY2024Q4 us-gaap Accelerated Share Repurchases Final Price Paid Per Share
AcceleratedShareRepurchasesFinalPricePaidPerShare
64.7

Files In Submission

Name View Source Status
0001811884-24-000022-index-headers.html Edgar Link pending
0001811884-24-000022-index.html Edgar Link pending
0001811884-24-000022.txt Edgar Link pending
0001811884-24-000022-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
report.css Edgar Link pending
Show.js Edgar Link pending
utmd-20240930.htm Edgar Link pending
utmd-20240930.xsd Edgar Link pending
utmd_ex31z1.htm Edgar Link pending
utmd_ex31z2.htm Edgar Link pending
utmd_ex32z1.htm Edgar Link pending
utmd_ex32z2.htm Edgar Link pending
utmd-20240930_cal.xml Edgar Link unprocessable
utmd-20240930_def.xml Edgar Link unprocessable
utmd-20240930_lab.xml Edgar Link unprocessable
utmd-20240930_pre.xml Edgar Link unprocessable
utmd-20240930_htm.xml Edgar Link completed